PepTalk 2017
PepTalk 2017

Pipeline Three Header

Cambridge Healthtech Institute’s Ninth Annual
Optimizing Biologics Formulation Development
Formulation Strategies in an Era of Accelerated Timelines, New Product Formats and Novel Delivery Systems
January 9-10, 2017 | Hilton San Diego Bayfront | San Diego, CA


Each year, the PepTalk Optimizing Biologics Formulation Development meeting brings together an international audience of analytical and formulation scientists from leading industry companies to hear solutions to the most significant challenges in their field. For 2017, the conference focuses on the science and strategies of formulation development in an era of compressed timelines, novel molecular and product formats and products based on novel device and packaging systems.

Preliminary Agenda


EARLY STAGE MOLECULAR ASSESSMENT


KEYNOTE PRESENTATION: Formulation Development in the Rapidly Evolving Biotechnology Environment

Nicholas Warne, Ph.D., Director, Formulations, Pfizer

Techniques and Strategies for Evaluating Developability of Novel Modalities

Francis Kinderman, Ph.D., Senior Scientist, Drug Product and Formulation Technologies, Amgen

 

FORMULATION IMPACTS OF PRODUCT AND DOSAGE FORM DESIGN

Patient Centricity and System Integration as New Drivers of Biologic Drug Product Design Strategy

Didier Pertuy, Vice President, Global Drug Device Integrated Development, Sanofi, France

Early Device and Container Closure System Evaluation

Adam McCullough, ‪Principal Engineer, Advanced Device Technologies, Amgen

Overcoming the Challenges in Developing Multi-Dose Formulations of Aggregation-Prone Peptides

Jingtao Zhang, Ph.D., Principal Scientist, Pharmaceutical Sciences, Merck Research Laboratories


FORMULATION DEVELOPMENT FOR NOVEL MODALITIES

Pushing Formulation Development into Discovery through Antibody Design and High-Throughput Screening

Bruce Kerwin, Ph.D., ‪Vice President, Drug Product Design, Just Biotherapeutics

Formulation Development for Dual Affinity Antibody-Based Molecules

Krishnan Sampath, Ph.D., ‪Senior Director, Drug Product Sciences, MacroGenics, Inc.‬‬‬‬‬‬

Formulation Development for Combination Drug Products

Murali Bilikallahalli, Ph.D., Associate Director, Vaccines & Biologics, MedImmune LLC

Development of Formulations Containing Monoclonal Antibodies and Recombinant Hyaluronidase

Claudia Mueller, Ph.D., Senior Scientist, Late-Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, F. Hoffmann-La Roche Ltd., Switzerland

Formulation Development for Novel Antibody Drug Conjugates

Mike Fleming, Ph.D., Scientist, Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.


INNOVATION

Evaluation of Emerging Analytical Method and Instrument Combinations

Steve LaBrenz, Ph.D., Scientific Director, Janssen R&D LLC

New Grade of Polysorbate to Overcome Particle Formation

John Wang, Ph.D., Group Leader and Principal Scientist, Genentech


FORMULATION CHALLENGES DURING CLINICAL DEVELOPMENT

Clinical Stage Evaluation of a Biologic Formulation Using Novel Robustness Diagrams

Radhakrishna Maroju, Ph.D., Senior Scientist, Drug Product Development and Operations, Teva Biopharmaceuticals

In-Use Stability Evaluations for Enabling Low Dose Intravenous Administration

Xiaofeng Lu, Ph.D., Principal Research Scientist, AbbVie Biotherapeutics Inc.




For questions about the meeting, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199
Email: ksimmons@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com